

# CHEMO PHARMA LABORATORIES LIMITED

- EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001
  - TEL: 91-22-22078381, 22078382 • FAX: 91-22-22074294
  - CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
- [www.thechemopharmalaboratoriesltd.com](http://www.thechemopharmalaboratoriesltd.com)  
 EMAIL: [chemopharmalab@gmail.com](mailto:chemopharmalab@gmail.com)

## Quarterly Compliance Report on Corporate Governance under Clause 49 of the Listing Agreement

Name of the Company: CHEMO PHARMA LABORATORIES LIMITED

Quarter ending on: 30/09/2014

Particulars	Clause of Listing Agreement	Compliance Status Yes/No	Remarks
<b>I Board of Directors</b>	49 I	Yes	
(A) Composition of Board	49(I)(A)	Yes	Optimum Combination of Executive, Non-Executive and Independent Directors in Board. There are Four Directors of which two are Executive Directors, and two are Non-Executive Independent Directors. The Chairman of the Board is Executive Promoter Director. The number of Non-Executive Independent Directors is fifty percentage of the total strength of the Board. The Independent Directors fulfill their criterion as prescribed in Clause 49 (iii) of the Listing Agreement.
(B) Non-executive Directors' Compensation & Disclosures	49 (I)(B)	Yes	Non-Executive Directors have not been paid any remuneration. Necessary disclosure has been made in the Annual Report for the year 2013-14.
(C) Other Provisions as to Board and Committees	49 (I)(C)	Yes	Provisions complied. Maximum time gap is not more than four months between two Board Meetings.



D) Code of Conduct	(49 (I)(D)	Yes	Approved by Board of Directors and disclosed in Annual Report. Also adopted revised Code of Conduct in the Meeting of the Board of Directors.
<b>II. Audit Committee</b>	49 (II)	Yes	
(A) Qualified & Independent Audit Committee	49 (II)(A)	Yes	The Audit Committee comprises of three members, out of which two Directors are Non-Executive Independent Director and One is Executive Director. All are Financially Literate and one member possess requisite financial and Management Expertise. The Chairman of the Audit Committee is Non-Executive Independent Director.
(B) Meeting of Audit Committee	49 (IIB)	Yes	Atleast four Board Meetings of Audit Committee are held in a Financial year.
(C) Powers of Audit Committee	49 (II)(C)	Yes	Powers of Audit Committee duly defined and the same are as per Clause 49 II (C) of Listing Agreement
(D) Role of Audit Committee	49 II(D)	Yes	Role of Audit Committee duly defined and the same are as per Clause.49 II (D) of Listing Agreement.
(E) Review of Information by Audit Committee	49 (II)(E)	Yes	Required review is done regularly.
<b>III. Subsidiary Companies</b>	49 (III)	N.A	There is no Subsidiary Company.
<b>IV. Disclosures</b>	49 (IV)	Yes	
(A) Basis of Related Party Transactions	49 (IV) (A)	Yes	The Related Party Transactions in which Directors of the Company are interested have been duly disclosed in the Annual Report for the year ended 31 <sup>st</sup> March, 2014.
(B) Disclosure of Accounting Treatment	49 (IV) (B)	Yes	Duly disclosed in Audited Annual Report for the year ended 31 <sup>st</sup> March 2014.



(C) Board Disclosures	49 (IV) (C)	Yes	The Board has laid down procedures about risk Assessment and minimization procedures and the same are reviewed periodically by the Board.
(D) Proceeds from Public Issues, Rights Issues, Preferential Issues etc.	49 (IV) (D)	Yes	No Public/ Right Issue has been made during the Current Year. Proceeds of earlier issues utilized for the purpose are stated in prospectus, offer documents.
(E) Remuneration of Directors	49 (IV) (E)	Yes	There is no pecuniary relationship or transactions with any of the Independent Directors. The Non-Executive Directors are not paid any sitting fees. The remuneration paid to Executive Director is duly disclosed.
(F) Management	49 (IV) (F)	Yes	Management Discussion and Analysis Report forms part of Annual Report for the year ended 31 <sup>st</sup> March, 2014.
(G) Shareholders	49 (IV) (G)	Yes	The Shareholders/ Investors Grievance Committee comprises of three members, One is Non-Executive Director and two are Independent Directors. The Chairman of the Shareholders/ Investors Grievance Committee is an Independent Director.
<b>V.CEO/CFO Certification</b>	49 (V)	Yes	CEO/CFO Certificate included in report of Corporate Governance forms part of the Audited Annual Report for the year ended 31 <sup>st</sup> March, 2014. There was Appointment of Smt. Shanta Somani as CEO in place of Shri. Ashok Somani along with appointment of Shri. Ashok Somani as CFO in place of Ashok Joshi in



			the Board Meeting held on 26.09.2014.
<b>VI. Report on Corporate Governance</b>	49 (VI)	Yes	Corporate Governance Report forms part of the Directors Report in the Annual Report for 31 <sup>st</sup> March, 2014.
<b>VII. Compliance</b>	49 (VII)	Yes	Duly Complied

**FOR CHEMO PHARMA & LABORATORIES LIMITED**

**Place: Mumbai**

**Date: 14<sup>th</sup> October, 2014**

*Ashok Somani*

**ASHOK SOMANI  
DIRECTOR**

**(DIN NO. - 03063364)**

